Wave Life Sciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) has announced its participation in two major investor conferences this December. Paul Bolno, MD, MBA, President and CEO, will represent the company at both events. The first appearance will be an analyst-led fireside chat at the 7th Annual Evercore HealthCONx Conference on December 3, 2024, at 3:00 p.m. ET. The following day, December 4, he will participate in a Neuromuscular Disorders panel at the Citi 2024 Global Healthcare Conference at 1:00 p.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for a time.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December.
7ᵗʰ Annual Evercore HealthCONx Conference
Date: Tuesday, December 3, 2024
Analyst-led fireside chat: 3:00 p.m. ET
Citi 2024 Global Healthcare Conference
Date: Wednesday, December 4, 2024
“Neuromuscular Disorders” panel: 1:00 p.m. ET
Live webcasts of these presentations can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of these presentations will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
FAQ
When is Wave Life Sciences (WVE) presenting at the Evercore HealthCONx Conference in December 2024?
What panel is Wave Life Sciences (WVE) participating in at the Citi 2024 Global Healthcare Conference?
Where can investors watch Wave Life Sciences' (WVE) December 2024 conference presentations?
